Organon & Co. (NYSE:OGN) Price Target Lowered to $16.00 at Morgan Stanley

Organon & Co. (NYSE:OGN) had its target price reduced by investment analysts at Morgan Stanley from $17.00 to $16.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s price target suggests a potential upside of 0.45% from the company’s current price.

Separately, TD Cowen raised Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, three have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $20.00.

Organon & Co. Trading Down 2.4 %

Shares of NYSE OGN traded down $0.39 during midday trading on Friday, hitting $15.93. The company’s stock had a trading volume of 306,014 shares, compared to its average volume of 2,685,254. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The business’s 50 day moving average is $15.34 and its two-hundred day moving average is $17.53. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10. The firm has a market cap of $4.10 billion, a P/E ratio of 3.20, a price-to-earnings-growth ratio of 0.83 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. As a group, equities research analysts expect that Organon & Co. will post 3.82 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC grew its stake in Organon & Co. by 238.0% in the third quarter. Barclays PLC now owns 119,483 shares of the company’s stock worth $2,285,000 after purchasing an additional 84,136 shares in the last quarter. Weiss Asset Management LP bought a new stake in Organon & Co. during the 3rd quarter valued at $32,966,000. Cerity Partners LLC boosted its position in Organon & Co. by 94.0% during the 3rd quarter. Cerity Partners LLC now owns 667,340 shares of the company’s stock valued at $12,766,000 after acquiring an additional 323,308 shares in the last quarter. Foundry Partners LLC bought a new stake in Organon & Co. during the 3rd quarter valued at $7,642,000. Finally, Beddow Capital Management Inc. boosted its position in Organon & Co. by 38.8% during the 3rd quarter. Beddow Capital Management Inc. now owns 306,675 shares of the company’s stock valued at $5,867,000 after acquiring an additional 85,775 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.